7-(hydroxymethyl)theophylline | 31542-43-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: 7-(hydroxymethyl)theophylline
• 英文别名: N7-hydroxymethyltheophylline；7-hydroxymethyl-1,3-dimethyl-3,7-dihydro-purine-2,6-dione；7-Hydroxymethyl-1,3-dimethyl-3,7-dihydro-purin-2,6-dion；1,3-dimethyl-7-hydroxymethylxanthine；7-hydroxymethyl theophylline；7-(hydroxymethyl)-1,3-dimethylpurine-2,6-dione
• CAS: 31542-43-5
• 化学式: C₈H₁₀N₄O₃
• 分子量: 210.192
• InChiKey: QAPJAMJGLYYNHX-UHFFFAOYSA-N

物化性质

• 熔点：
  261-262 °C (decomp)(Solv: ethanol (64-17-5))
• 沸点：
  480.0±51.0 °C(Predicted)
• 密度：
  1.59±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -1.1
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  78.7
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  7-(hydroxymethyl)theophylline 在 氯化亚砜 作用下， 以 二氯甲烷 为溶剂， 反应 2.0h， 以95%的产率得到N7-chloromethyltheophylline
  参考文献：
  名称：

  定向C–H活化合成带有C8金属化茶碱配体的铱（III）和铑（III）配合物

  摘要：

  提出了N-供体系茶碱与铱（III）和铑（III）在C8位置的直接C–H活化作用。N系供体组的供体强度有所不同。带有强供体咪唑啉-2-亚基或较弱供体吡啶基的配体均在相似的条件下被金属化，这表明金属中心的电子密度在CH活化步骤中不发挥重要作用。通过羧酸盐辅助途径进行。带有螯合C NHC ^ C azolato配体（M = Ir：[ 4 ]，M = Rh：[ 5 ]）和N吡啶^ C azolato的铱（III）和铑（III）配合物的合成与表征报告了配体（M ＝ Ir：[ 7 ]，M ＝ Rh：[ 8 ]）。另外，分离并表征了作为C NHC ^ C azolato络合物的前体的NHC络合物（M = Ir：[ 2 ]，M = Rh：[ 3 ]）。

  DOI：

  10.1021/acs.organomet.9b00184
• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 乙醇 作用下， 生成 7-(hydroxymethyl)theophylline
  参考文献：
  名称：

  Notes- Theophylline in the Mannich Reaction

  摘要：

  DOI：

  10.1021/jo01086a605

文献信息

• Potential Metabolic Mutagens of Caffeine and Various Methylxanthines
  作者：Naphtali Lander、Albert H. Soloway、John P. Minton、Bhupat D. Rawal、Chandra C. Gairola

  DOI：10.1002/jps.2600771112

  日期：1988.11

  Xanthine N-carbinols, potential metabolites of caffeine and other methylxanthines, have been synthesized, characterized, and derivatized. Such intermediates, the initial metabolites arising from the cytochrome P-450 oxidation of the nitrogen-bound methyl groups, may be viewed as biological N-carbinols capable of alkylating proteins and nucleic acids. Evaluation of these compounds against Salmonella

  黄嘌呤N-卡宾醇，咖啡因和其他甲基黄嘌呤的潜在代谢产物，已经合成，表征和衍生化。这样的中间体，是由氮结合的甲基的细胞色素P-450氧化产生的初始代谢物，可以看作是能够使蛋白质和核酸烷基化的生物N-甲醇。对这些化合物针对鼠伤寒沙门氏菌TA100菌株的评估表明，与咖啡因相反，7-羟甲基茶碱和3,7-双（羟甲基）-1-甲基黄嘌呤混合物确实表现出细胞毒性。没有诱变的证据，Ames分析系统可能不适用于N-甲醇。
• Transient pro-drug forms of xanthine derivatives and their use as
  申请人：INTERx Research Corporation

  公开号：US04275064A1

  公开（公告）日：1981-06-23

  Compounds of the formula: ##STR1## useful in treating dermal inflammation in warm-blooded animals are provided.

  提供了化学式为##STR1##的化合物，用于治疗温血动物的皮肤炎症。
• Treating psoriasis with transient pro-drug forms of xanthine derivatives
  申请人：INTERx Research Corporation

  公开号：US04061753A1

  公开（公告）日：1977-12-06

  Compounds of the formula: ##STR1## wherein R, which may be the same or different, represents a member selected from the group consisting of --CH.sub.3, --C.sub.2 H.sub.5, --C.sub.3 H.sub.7, iso--C.sub.3 H.sub.7, --C.sub.4 H.sub.9, iso--C.sub.4 H.sub.9, pentyl, benzyl, allyl, 2-hydroxyethyl, cyclohexyl, 2-isobutenyl, hydroxymethyl, 2-phenylethyl and -CH.sub.2 O-R.sub.2, wherein R.sub.2 is defined infra; wherein R.sub.1 represents a member selected from the group consisting of H, C.sub.1 -C.sub.7 straight or branched alkyl, CCl.sub.3, CBr.sub.3, CI.sub.3, ##STR2## CH.sub.3 O--CH.sub.2 --, (CH.sub.3).sub.2 NCH.sub.2 --, ##STR3## wherein R.sub.3 represents a member selected from the group consisting of -OH, halogen (Cl, Br, I), --OCH.sub.3, -COOCH.sub.3, -NO.sub.2 and -OCOCH.sub.3 ; wherein ##STR4## and wherein R.sub.2 represents a member selected from the group consisting of ##STR5## wherein R.sub.4 is a member selected from the group consisting of C.sub.2 -C.sub.20 straight or branched alkyl (C.sub.3 -C.sub.7 preferred), --[--(CH.sub.2).sub.m --], wherein m represents an integer of from 0 to 10, ##STR6## wherein R.sub.3 is defined as above, ##STR7## the residue of any naturally occurring amino acid, the residue of any N- substituted amino acid, wherein said substituent is any amino acid protective group cleavable via hydrogenolysis or hydrolysis (e.g., formyl, benzyloxy, carbonyl, t-butyloxycarbonyl), the residue of an N,N-C.sub.1 -C.sub.5 -dialkyl or cycloalkylamino acid, ##STR8## wherein n represents an integer of from 1-5 and R.sub.5 and R.sub.6 which may be the same or different represent C.sub.1 -C.sub.5 alkyl or together form a heterocyclic ring with the N atom to which they are attached (e.g., pyrolidine, piperidine, morpholine, piperazine, imidazoline, thiazolidine, isoxazolidine), imidazolyl, O-C.sub.1 -C.sub.8 alkyl, O-benzyl, O-phenyl and ##STR9## wherein n, R.sub.5 and R.sub.6 are defined as above; and wherein R.sup.2 further represents a member selected from the group consisting of straight or branched C.sub.1 -C.sub.20 alkyl, ##STR10## wherein n, R.sub.5 and R.sub.6 are defined as above, phenyl, tolyl, xylyl, and --SO.sub.2 --R.sub.7, wherein R.sub.7 is a straight or branched C.sub.1 -C.sub.20 alkyl useful in treating psoriasis in warm-blooded animals are provided.

  提供一种公式为：##STR1##其中R，可以相同或不同，代表从群组中选择的成员，该群组包括--CH.sub.3，--C.sub.2 H.sub.5，--C.sub.3 H.sub.7，iso--C.sub.3 H.sub.7，--C.sub.4 H.sub.9，iso--C.sub.4 H.sub.9，戊基，苄基，烯丙基，2-羟基乙基，环己基，2-异丁烯基，羟甲基，2-苯乙基和-CH.sub.2 O-R.sub.2，其中R.sub.2如下所定义;其中R.sub.1代表从群组中选择的成员，该群组包括H，C.sub.1-C.sub.7直链或支链烷基，CCl.sub.3，CBr.sub.3，CI.sub.3，##STR2##CH.sub.3 O--CH.sub.2 --，(CH.sub.3).sub.2 NCH.sub.2 --，##STR3##其中R.sub.3代表从群组中选择的成员，该群组包括-OH，卤素（Cl，Br，I），--OCH.sub.3，-COOCH.sub.3，-NO.sub.2和-OCOCH.sub.3;其中##STR4##其中R.sub.2代表从群组中选择的成员，该群组包括##STR5##其中R.sub.4是从群组中选择的成员，该群组包括C.sub.2-C.sub.20直链或支链烷基（C.sub.3-C.sub.7为首选），--[--(CH.sub.2).sub.m--]，其中m表示0到10的整数，##STR6##其中R.sub.3如上所定义，##STR7##任何天然氨基酸的残基，任何N-取代氨基酸的残基，其中所述取代基是通过氢解或水解可裂解的任何氨基酸保护基（例如，甲酰基，苄氧基，羰基，t-叔丁氧羰基），N，N-C.sub.1-C.sub.5-二烷基或环烷基氨基酸的残基，##STR8##其中n表示1-5的整数，R.sub.5和R.sub.6可以相同或不同，代表C.sub.1-C.sub.5烷基，或者与它们连接的N原子形成杂环环（例如，吡咯烷，哌嗪，吗啉，吡嗪，咪唑啉，噻唑烷，异噻唑啉），咪唑基，O-C.sub.1-C.sub.8烷基，O-苄基，O-苯基和##STR9##其中n，R.sub.5和R.sub.6如上所定义;并且R.sup.2进一步代表从群组中选择的成员，该群组包括直链或支链C.sub.1-C.sub.20烷基，##STR10##其中n，R.sub.5和R.sub.6如上所定义，苯基，甲苯基，二甲苯基和--SO.sub.2--R.sub.7，其中R.sub.7是用于治疗温血动物牛皮癣的直链或支链C.sub.1-C.sub.20烷基。
• Compounds having mucolytic and bronchodilating activity, a process for their preparation and pharmaceutical composition containing them as active principle
  申请人：PROTER S.p.A.

  公开号：EP0189101A2

  公开（公告）日：1986-07-30

  Novel compounds having mucolytic and bronchodilating activity, a process for their preparation consisting in the treatment of 7-hydroxymethyl-theophylline with succinis anhydride to give 7-succinoyloxymethyl-theophylline, which in turn is converted in an activated derivative to carry out the condensation reaction with the corresponding thiol; pharmaceutical formulations containing said compounds as active ingredients.

  具有粘液溶解和支气管扩张活性的新型化合物，其制备工艺包括用琥珀酸酐处理7-羟甲基茶碱，得到7-琥珀酰氧基甲基茶碱，然后将其转化为活化衍生物，与相应的硫醇发生缩合反应；含有上述化合物作为活性成分的药物制剂。
• DE254488
  申请人：——

  公开号：——

  公开（公告）日：——